Mercer Global Advisors
QNCX icon

Mercer Global Advisors’s Quince Therapeutics QNCX Stock Holding History

Mercer Global Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109 Buy
+6
New +$138 ﹤0.01% 5967

Other funds holding QNCX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
GWP
Gen-Wealth Partners Zeeland, Michigan $360M AUM 27.44% 1-Year Est. Return
OA
Operose Advisors Milwaukee, Wisconsin $517M AUM 24.68% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

Mercer Global Advisors's QNCX Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Quince Therapeutics (QNCX) in Q2 2026: 6 shares worth $109. The stake represents ﹤0.01% of the portfolio and ranks #5967 among its holdings.

16 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Mercer Global Advisors held 6 shares of Quince Therapeutics worth $109 as of Q2 2026.
  • Quince Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Quince Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5967 holding.
  • 16 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.